Removal notice to Effect of Intranasal Oxytocin Administration on Psychiatric Symptoms: A Meta-Analysis of Placebo-Controlled Studies Psychiatr Res. 228 (2015) 708-714

Hofmann, Stefan G.; Fang, Angela; Brager, Daniel N.

doi:10.1016/j.psychres.2018.04.028

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Woods et al (79,80) Prevention psychosis To investigate the safety and efficacy of ziprasidone in delaying or preventing conversion to psychosis among individuals meeting CHR-P criteria Yung et al (81); McGorry et al (66) Prevention psychosis Cognitive therapy and/or low-dose antipsychotic administered during the prodromal phase of schizophrenia may prevent or delay the onset of full-blown illness. hope of its potential as a treatment in established psychosis has been somewhat stifled by recent negative meta-analytic findings (92,93). Nevertheless, neuroimaging studies demonstrate that oxytocin can modulate various indices of brain function, both task-specific and at rest, and in regions critically implicated in the onset of psychosis, such as limbic and midbrain brain regions (94)(95)(96).…”

Section: Oxytocinmentioning

confidence: 99%

Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)

et al. 2019

View full text Add to dashboard Cite

Background: Indicated primary prevention in young people at Clinical High Risk for Psychosis (CHR-P) is a promising avenue for improving outcomes of one of the most severe mental disorders but their effectiveness has recently been questioned. Methods: Umbrella review. A multi-step independent literature search of Web of Science until January 11, 2019, identified interventional meta-analyses in CHR-P individuals. The individual randomised controlled trials that were analysed by the meta-analyses were extracted. A review of ongoing trials and a simulation of living meta-analysis complemented the analysis. Results: Seven meta-analyses investigating preventive treatments in CHR-P individuals were included. None of them produced pooled effect sizes across psychological, pharmacological, or other types of interventions. The outcomes analysed encompassed risk of psychosis onset, the acceptability of treatments, the severity of attenuated positive/negative psychotic symptoms, depression, symptom-related distress, social functioning, general functioning, and quality of life. These meta-analyses were based on 20 randomised controlled trials: the vast majority defined the prevention of psychosis onset as their primary outcome of interest and only powered to large effect sizes. There was no evidence to favour any preventive intervention over any other (or control condition) for improving any of these clinical outcomes. Caution is required when making clinical recommendations for the prevention of psychosis in individuals at risk. Discussion: Prevention of psychosis from a CHR-P state has been, and should remain, the primary outcome of interventional research, refined and complemented by other clinically meaningful outcomes. Stagnation of knowledge should promote innovative and collaborative research efforts, in line with the progressive and incremental nature of medical knowledge. Advancements will most likely be associated with the development of new experimental therapeutics that are ongoing along with the ability to deconstruct the high heterogeneity within CHR-P populations. This would require the estimation of treatment-specific effect sizes through living individual participant data meta-analyses,

show abstract